Rocuronium Bromide is a drug owned by B Braun Medical Inc. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 22, 2039. Details of Rocuronium Bromide's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11998605 | Stabilized Aqueous Compositions Of Neuromuscular Blocking Agents |
Jul, 2039
(13 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Rocuronium Bromide's patents.
Latest Legal Activities on Rocuronium Bromide's Patents
Given below is the list of recent legal activities going on the following patents of Rocuronium Bromide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Electronic Review | 07 Jun, 2024 | US11998605 |
| Patent eGrant Notification | 04 Jun, 2024 | US11998605 |
| Recordation of Patent Grant Mailed | 04 Jun, 2024 | US11998605 |
| Email Notification | 04 Jun, 2024 | US11998605 |
| Patent Issue Date Used in PTA Calculation | 04 Jun, 2024 | US11998605 |
| Recordation of Patent eGrant | 04 Jun, 2024 | US11998605 |
| Mail Patent eGrant Notification | 04 Jun, 2024 | US11998605 |
| Email Notification | 16 May, 2024 | US11998605 |
| Issue Notification Mailed | 15 May, 2024 | US11998605 |
| Dispatch to FDC | 29 Apr, 2024 | US11998605 |
US patents provide insights into the exclusivity only within the United States, but
Rocuronium Bromide is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Rocuronium Bromide's family patents as well as insights into
ongoing legal events
on those patents.
Rocuronium Bromide's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Rocuronium Bromide's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 22, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Rocuronium Bromide Generic API suppliers:
Rocuronium Bromide is the generic name for the brand Rocuronium Bromide. 21 different companies have already filed for the generic of Rocuronium Bromide, with West Ward Pharm Corp having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Rocuronium Bromide's generic
About Rocuronium Bromide
Rocuronium Bromide is a drug owned by B Braun Medical Inc. Rocuronium Bromide uses Rocuronium Bromide as an active ingredient. Rocuronium Bromide was launched by B Braun in 2025.
Approval Date:
Rocuronium Bromide was approved by FDA for market use on 24 October, 2025.
Active Ingredient:
Rocuronium Bromide uses Rocuronium Bromide as the active ingredient. Check out other Drugs and Companies using Rocuronium Bromide ingredient
Dosage:
Rocuronium Bromide is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 50MG/5ML (10MG/ML) | SOLUTION | Prescription | INTRAVENOUS |